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1. What is known on this topic 
• Platelets produce ROS in response to activation during thrombosis 
• Exogenous Zinc acts as platelet agonist 
• Zinc is an intracellular secondary messenger in platelets 
• ROS production is regulated by NADPH oxidases, and involves signalling via 
MAPK family members 
 
2. What this paper adds 
• Fluctuations of intracellular Zn2+ in platelets regulates ROS production 
• Zn2+-dependent ROS production is dependent on NADPH oxidase and 
mitochondria activity, and is regulated by Erk1/2 and JNK  




Vascular complications resulting from atherosclerosis development are a major cause 
of death. Reactive oxygen species (ROS) are produced by platelets during activation, 
and have been demonstrated to positively regulate platelet activatory responses. Zn2+ 
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is also an important haemostatic cofactor in platelets, acting both as a platelet agonist 
and secondary messenger. Whilst the effect of Zn2+-dependent signalling mechanisms 
on ROS production in nucleated cells has been demonstrated, comparable roles in 
platelets have yet to be investigated. In this study we investigate the relationship 
between fluctuations in cytosolic Zn2 [Zn2+]i and platelet ROS production. Agonist-
evoked ROS production, GSH levels and GPx activity are abrogated in platelets 
treated with the Zn2+-chelator, TPEN. Conversely, increasing platelet [Zn2+]i using Zn2+ 
ionophores potentiated ROS generation and decreased GSH levels and GPx activity. 
Zn2+-dependent ROS production was sensitive to pretreatment with DPI or 
mitoTEMPO, a NADPH oxidase and mitochondria inhibitors respectively. Increasing 
[Zn2+]i resulted in increases of Erk1/2 and JNK phosphorylation. Our data are 
consistent with a functional association between [Zn2+]i and ROS production in 
platelets that could influence thrombus formation in a clinical context. 
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Complications resulting from atherosclerosis development are a major cause 
of mortality and morbidity.[1] Atherosclerotic plaques develop as a result of chronic 
inflammation, with inflammatory signals activating endothelial cells, leading to 
leukocyte infiltration. Platelets also cooperate in inflammatory processes leading to 
plaque development and tissue reconstruction.[1,2] The evolution of atherosclerotic 
plaques and their subsequent rupture, are responsible for myocardial infarction and 
stroke.[3] 
Zinc (Zn2+) is an important regulator of intra- and extracellular physiological 
processes in a variety of cell types. Local, extracellular Zn2+ levels significantly 
increase in the initial inflammatory phase following injury, and have been shown to 
facilitate wound healing.[4,5] Furthermore, levels of Zn2+ in atherosclerotic plaques are 
approximately six times greater than in healthy tissues.[6] As Zn2+ is present in the α 
granules of platelets, degranulation is likely to result in localised increases in Zn2+,[7] 
which could regulate haemostatic processes. Zn2+ has been shown to have important 
functions in haemostasis. Bleeding irregularities are correlated with low zinc diets in 
humans and rodents.[8,9] Exogenous Zn2+ acts as a platelet agonist, being able to 
cross platelet membranes to initiate platelet aggregatory mechanisms in a manner that 
is dependent on PKC.[10,11] Recent work has demonstrated that intracellular Zn2+ 
([Zn2+]i) increases in the platelet cytosol as a result of agonist stimulation, an a manner 
consistent with a secondary messenger.[12] In this work it was shown that agonist-
evoked increases in [Zn2+]i were sensitive to the platelet redox state, suggestive 
of a role for thiol groups on Zn2+ binding proteins. 
Whilst reactive oxygen species (ROS) are produced as a result of the habitual 
metabolism of cells, chronic and acute overproduction of ROS is associated with the 
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development of cardiovascular disease, hypertension, diabetes, 
hypercholesterolemia, thrombotic diseases and metabolic syndrome.[13–16] The 
principal forms of ROS are superoxide anion (O2•-), hydrogen peroxide (H2O2), 
hydroxyl radicals (OH•), and hypochlorous acid (HOCl). These are endogenously 
produced from distinct sources via the action of enzymes including NADPH oxidase, 
xanthine oxidase, lipoxygenase, cyclooxygenase, and components of the 
mitochondria electron transport chain. [17]. In low concentrations, ROS plays a role in 
the function of cell processes .[19] At higher concentrations, ROS production results 
in damage to cell components, including lipids, nucleic acids and proteins.[20] This 
damage impairs regular cell activity and can lead to the release of secondary reactive 
species which can do further damage, contributing to a development of different 
diseases.[16,21–23]  
The mechanisms that lead to the release of ROS from nucleated cells have 
been investigated, and the involvement of Zn2+ in this process has been assessed. 
Treatment of cells with Zn2+ promotes increases in ROS generation as a result of 
NADPH oxidase activity.[24,25] Zn2+-treatment results in damage to renal cells in vitro, 
concomitantly with a raise of ROS release and promote the activation of p67phox, a  
NADPH oxidase subunit.[26] ROS production in numerous cell types correlates with 
Zn2+-dependent regulation of NOX expression [27,28] and mitochondria activation[29–
31]. However, the effect of exogenous or endogenous Zn2+ on ROS production in 
platelets is yet to be investigated. Here, we show that increasing [Zn2+]i, via either 
exogenously applied Zn2+ or agonist evoked increases in [Zn2+]i regulates ROS 
generation in a manner that is dependent on NADPH oxidase and mitochondria 
activation, and is regulated by MAPK phosphorylation. These data indicate that 
increases in platelet [Zn2+]i either from ruptured atherosclerotic plaques, or from 
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MATERIALS AND METHODS 
 
Materials 
Cross-linked collagen-related peptide (CRP-XL; GpVI agonist) was from 
Professor Richard Farndale (Cambridge, UK), U46619 (TPα receptor agonist) was 
from Tocris (Bristol, UK), thrombin (PAR agonist) was from Sigma Aldrich (Poole, 
UK).The cell-permeable superoxide indicator dihydroethidium (DHE) was from Abcam 
(Cambridge, UK). The NADPH oxidase inhibitor diphenyleneiodonium chloride (DPI) 
was from Tocris. The mitochondrial targeted anti-oxidant, mitoTEMPO was from 
Sigma Aldrich (Poole, UK) Clioquinol, (Cq, Zn2+ ionophore, C9H5ClINO, KdZn: 10-7M, 
KdCa: 10-4.9M), A23187 (Ca2+ ionophore, C29H37N3O6), N,N,N′,N′-Tetrakis(2-
pyridylmethyl) ethylenediamine (TPEN, Zn2+ chelator, KdZn: 2.6x10-16M, KdCa: 4.4x10-
5M), DM-BAPTA-AM (C34H40N2O18, KdZn: 7.9×10−9M, KdCa: 110×10−9M), and 
membrane permeant anti-oxidising proteins, PEG-Super oxidise dismutase (SOD) 
and PEG-Catalase (CAT) were from Sigma Aldrich.  
The NADPH oxidase inhibitor DPI and the mitochondrial-targeted antioxidant 
inhibitor mitoTEMPO were from Sigma. 
For immunoblotting, specific antibodies against various signalling proteins 
(phospho-Erk1/2 (Thr202/Tyr204), phospho-JNK (Thr183/Tyr185), p47phox, 
phospho-p47phox) were obtained from Santa Cruz Antibodies, USA or Thermofisher, 
UK (sc136521, sc293136, sc6254, sc17845 and PA5 36863 respectively). Rabbit β-
actin antibody was from (Cell Signalling, UK; #4970). Secondary antibodies Cy5 goat 
anti-rabbit IgG and Cy3 goat anti-mouse IgG antibodies were obtained from Cell 
Signalling. Cell-permeable superoxide-specific spin probe 3-methoxycarbonyl-2,2,5,5-
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This study was approved by the Faculty Research Ethics Committee at Anglia Ruskin 
University and informed consent was obtained in accordance with the Declaration of 
Helsinki. Blood was donated by healthy human volunteers, free from medication for 
two weeks. Blood was collected into 11mM sodium citrate and washed platelets were 
prepared as described previously.[11] 
 
DHE-based detection of platelet ROS by flow cytometry 
Platelet suspensions (2×108 cells/mL) were rested for 30mins at 37°C, prior to being 
loaded with 10μM of dihydroethidium (DHE) for 15mins in the dark at 37°C. Platelets 
were pre-incubated for 15mins with diphenyleneiodonium (DPI, 10µM), mitoTEMPO 
(10µM), TPEN (50µM), U0126 (10µM) and SP600 (10µM) prior to stimulation with 
ZnSO4 (10-300μM), Clioquinol (100μM), or A23187 (100μM). To investigate the 
influence of Zn2+ on agonist evoked ROS responses, platelets were pre-treated for 10 
minutes with TPEN (50μM) prior to stimulation with thrombin (1U/mL) or CRP-XL 
(1μg/mL). Following treatment, platelets suspensions were diluted 1:10 in cold 
modified Ca2+-free Tyrodes buffer (CFT, in mM: 140 NaCl, 5 KCl, 10 HEPES, 5 
Glucose, 0.42 NaH2PO4, 12 NaHCO3, pH7.4) and were analysed by flow cytometry 
using an Accuri C6 flow cytometer (BD, UK). Data were acquired from 10,000 cells 
and recorded as percentage of cells positive or median fluorescence intensity (MFI). 
 
Oxygen radical detection using Electron Spin Resonance (ESR) 
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As previously described [19], washed platelet suspensions (2×108/mL) were loaded 
with CMH (200μM, in the presence of 25µM deferoxamine and 5µM DETC) for 10 
minutes at room temperature. Platelet suspensions were loaded onto a Chronolog 
700-2 aggregometer with continuous stirring (1,200rpm at 37°C) and the turbidimetry 
readings were recorded. After 1 minute, ZnSO4 (10-300µM), clioquinol (100µM) or 
A23187 (100µM) were added and aggregation was measured for 10 minutes. 
Following aggregation, platelet solution was centrifuged by 14,000 g and 50µl of 
platelet-free supernatant was transferred into the Hirschmann precision micropipettes 
and read using an e-scan (Noxygen, Germany). ESR spectra were recorded using the 
following ESR settings: centre field 3,492.5G, field sweep 60G, modulation 
amplitude 2G, sweep time 10s, number of scans 10, microwave frequency 
9.39GHz, microwave power 20mW, conversion time, 327.68ms, time constant, 
5242.88ms..  
 
Reduced Glutathione (GSG) content and Glutathione Peroxidase (GPx) activity 
Washed platelet suspensions (2×108/mL) were stimulated with Clioquinol (100μM) or 
A23187 (100μM), or pre- incubated with TPEN (50μM) for 10 min prior to stimulation 
with thrombin (1U/mL) or CRP-XL (1μg/mL). Platelet GSH and GPx activity were 
determined by AmplteTM Fluorimetric Glutathione Assay Kit from AAT Bioquest® and 
EnzyChromTM Glutathione Peroxidase Assay Kit from BioAssay Systems, 
respectively, as described previously.[16,32] 
 
Confocal microscopy 
 Washed platelet suspensions (2×108/mL) were loaded with 10µM DHE in the dark for 
15 minutes at 37°. Suspensions were incubated with Clioquinol (100μM), A23187 
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(100μM), and adhere to fibrinogen-coated coverslips (100µM), during which images 
were acquired using a LSM510/Axiovert laser scanning confocal microscope with 60x 
oil NA1.45 objective (Zeiss, UK). Excitation and emission wavelengths were 420 and 
590 nm respectively 
 
Immunoblot assay 
SDS-PAGE and immunoblotting were performed using standard protocols as 
described previously.[33] Rabbit β-actin antibody (Cell Signalling, UK; catalogue 
number: #4970) was used to ensure equivalent levels of protein. Blots were visualised 
using enhanced chemiluminescence solution (ECL) (GE healthcare, UK). ImageJ 
(v1.45, NIH, Bethesda, USA) was used for quantification of protein bands. 
 
Data Analysis 
Data were analysed in GraphPad Prism by two-way ANOVA followed by 
Tukey’s post hoc test. Data are means ± SEM of at least four independent 







External Zn2+ induces ROS generation by unstimulated platelets 
The recruitment of platelets to areas of endothelial damage, followed by platelet 
activation, culminates in thrombus formation.[2,34] Activated platelets release ROS, 
potentially affecting platelets and other cells in a paracrine manner.[35] Whilst 
exogenous Zn2+ has been found to act as a platelet agonist [11,12,36], the effect of 
Zn2+ on platelet ROS production have yet to be investigated. Changes in ROS 
production in response to increasing concentrations of ZnSO4 (10-300μM), was 
investigated in washed platelet suspensions loaded with DHE,. Using fluorometry, 
DHE fluorescence increased following treatment with low concentrations of Zn2+. DHE 
fluorescence (AU) increased from a basal level of 551±52, to 1767±146, 1100±108, 
785±53 and 996±131 following treatment with 10, 30, 100 and 300µM of ZnSO4 
respectively (p<0.05, Figure 1a).  
ESR was employed to analyse superoxide anion production, as this is the most 
direct and reliable technique to identify chemical species that present one or more 
unpaired electrons.[14] Platelets were loaded with the cell-permeable superoxide-
specific spin probe CMH (200μM) prior to ESR analysis. Treatment with Zn2+ (10-
300µM) resulted in changes to ESR intensity from basal levels (a representative ESR 
trace is shown in Figure 1b), confirming that Zn2+ treatment increases ROS production 
in platelets. 
 
[Zn2+]i is required for agonist dependent ROS release 
Zn2+ is present in platelet α granules and also in the platelet cytosol where it is 
likely to associate with cation-binding proteins [12]. Platelet activation results in 
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increases in cytosolic Zn2+ concentration, consistent with release from intracellular 
stores.[12] To assess the influence of intracellular Zn2+ on ROS generation, platelet 
suspensions were preincubated with the intracellular Zn2+ chelator TPEN (50μM) prior 
to stimulation with thrombin (1U/mL) or CRP-XL (1μg/mL). In TPEN pretreated 
platelets, agonist-stimulated DHE fluorescence was reduced to basal levels. TPEN 
pretreatment reduced thrombin- or CRP-XL-mediated DHE fluorescence from 
7432±637 and 5951±255, to 4320±147 and 3690±195 respectively (p<0.05, Figure 
2a). 
The glutathione redox complex acts as a buffer, protecting cells from 
overproduction of ROS.[37] ROS production in platelets results in changes in the 
relative concentrations of reduced (GSH) and oxidised glutathione (GSSG), and also 
in degradation of GPx is to hydrogen peroxide (H2O2).[38] Levels of GSH and GPX 
activity in response to agonist stimulation in TPEN-pretreated platelets was quantified 
to investigate a role for Zn2+ in agonist-evoked ROS production. Stimulation of 
platelets with thrombin (1U/mL) or CRP-XL (1μg/mL) reduced GSH and GSH 
peroxidase (GPx) levels by approximately 50% and 30% respectively (Figures 2b, c). 
Thrombin and CRP-XL treatment reduced GSH to 0.39±0.03µM and 0.46±0.01µM 
respectively, relative to vehicle treatment (0.58±0.09µM). Similarly, GPx activity was 
reduced from 6.6±0.2U/mL to 4.7±0.12U/mL and 4.1±0.18U/mL in response to 
thrombin and CRP-XL respectively.  
Agonist evoked reductions of GSH levels and GPx activity were abrogated in 
TPEN pre-treatment platelets. TPEN induced an increase of 50% and 42.5% on GSH 
levels of platelets stimulated with thrombin and CRP-XL respectively, comparing with 
platelets in absence of TPEN (GSH level in TPEN-pretreated platelets was 
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0.78±0.06µM and 0.80±0.09µM following thrombin (1U/mL) or CRP-XL- (1µg/mL)-
mediated stimulation respectively). 
Similarly, GPx activity following stimulation was increased in TPEN-pretreated 
platelets relative to untreated platelets. GPx activity in TPEN pretreated platelets 
increased by approximately 30% and 24% following with thrombin and CRP-XL 
respectively (GPx activity in TPEN-pretreated platelets was 6.8±0.2 and 5.4±0.03 
following stimulation with thrombin and CRP-XL respectively, Figures 2b, c). These 
data are consistent with a role for [Zn2+]i in regulation of agonist-dependent ROS 
production. Whether this effect is attributable to agonist-evoked increases in 
[Zn2+]i,[12] or to the perturbation of obligate Zn2+-binding proteins is unclear. 
 
ROS generation is correlated with increases in [Zn2+]i  
Ionophores have previously been used to increase the concentration of 
cytosolic cations, mimicking cation release from intracellular stores.[39–41] Whilst 
A23187 has been widely used to investigate the effects of increases of cytosolic Ca2+ 
on cell or platelet function, it should be noted that this is a non-specific cation 
ionophore. Conversely, the Zn2+-specific ionophores clioquinol and pyrithione have 
previously been used to model increases in [Zn2+]i in platelets and other 
cells.[12,42,43] To analyse the effects of increases of Zn2+ on platelet ROS production. 
DHE-loaded platelets were stimulated with clioquinol (100µM), or A23187 (100µM) for 
10 minutes, and changes in fluorescence were quantified using flow cytometry. As 
previously described, [44] A23187 treatment increased DHE fluorescence to 
1735±176AU compared to the 745.±27AU for the vehicle control (DMSO, p<0.05, 
Figure 3a). Similarly clioquinol treatment resulted in increases of DHE fluorescence to 
1824±227AU (p<0.05, Fig. 3A). ESR revealed ionophore-dependent increases in ROS 
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production, with both A23187 and clioquinol increasing the oxidation rate of the spin 
probe CMH (Figure 3b). Changes in ionophore-mediated increases in ROS production 
were also assessed using confocal imaging of DHE-stained platelets. Treatment with 
A23187 or clioquinol both increased the number of DHE-positive platelets. Whilst both 
ionophores resulted in increases in ROS, the number of platelet staining positive 
following A23187 treatment was higher than that for clioquinol-treated platelets. Thus, 
increases in both [Zn2+]i and [Ca2+]i are able to mediated increases in ROS production 
(Figure 3c). 
To further assess the influence of increases in [Zn2+]i on ROS production, 
changes in GSH level and GPx activity in response to ionophore treatment were 
investigated. GSH levels and GPx activity decreased upon ionophore treatment 
(Figures 3d, e). Levels of GSH were reduced from 0.5±0.03µg/mL to 0.29±0.02µg/mL 
and 0.31±0.01 in response to A23187 or clioquinol respectively. Similarly, GPx activity 
was reduced from 6.8±0.15U/mL to 4.9±0.2U/mL and to 4.4±0.3U/mL following 
A23187 or clioquinol treatment respectively. These data indicate that increases of 
[Ca2+]i or [Zn2+]i result in a pro-oxidative state, potentially caused by increased ROS 
levels and subsequent modification of the glutathione redox system. 
 
[Zn2+]i-mediated ROS production is mediated by NADPH oxidase and 
mitochondrial activity. 
Both Ca2+ and Zn2+ have been shown to regulate ROS production via 
potentiation of independent mitochondria activity and NOX expression in nucleated 
cells.[27–31] To determine whether Zn2+-mediated ROS increases in platelets are due 
to NADPH oxidase or by activity of mitochondrial platelet, DHE-loaded platelets were 
treated with DPI (10µM) or mitochondrial mitoTEMPO (10µM) (a NADPH oxidase 
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inhibitor and mitochondria-targeted antioxidant, respectively) prior to stimulation 
with clioquinol (100µM) or A23187 (100µM), and ROS responses were quantified 
using flow cytometry. DHE fluorescence in DPI- and mitoTEMPO-pretreated platelets 
was reduced following stimulation with A23187 or clioquinol (Fig. 4A). A23187-
mediated ROS generation was reduced from 2170±149AU to 1013±161 and 
965±170AU in DPI and mitoTEMPO treated platelets respectively. Similarly, 
clioquinol-mediated ROS generation was reduced from 3240±381 to 9610±172 and 
919±140 in DPI and mitoTEMPO treated platelets respectively.  
NADPH oxidase activation is associated with phosphorylation events leading to 
association of various subunits under the control of p47phox.[45,46] Immunoblotting 
was performed to investigate whether ionophore-mediated increases of [Zn2+]i resulted 
in changes in the p47phox phosphorylation state. Treatment of washed platelet 
suspensions with A23187 or clioquinol resulted in increases in p47phox 
phosphorylation (from 0.75±0.03AU to 1.08±0.07AU and 1.14±0.1 following A23187 
and clioquinol treatment respectively, p<0.05, Figures 4b, c). This observation 
supports a role for NADPH oxidase in cation-dependent ROS production.  
 
Zn2+-mediated ROS generation induces Erk1/2 and JNK phosphorylation  
Zn2+-dependent activation of nucleated cells by Zn2+ is associated with 
concurrent MAPK activation.[47,48] To assess the effect of [Zn2+]i on MAPK- 
dependent signalling in platelets, we employed immunoblotting to quantify Erk1/2 
(Thr202/Tyr204) and JNK (Thr183/Tyr185) phosphorylation, in response to ionophore 
treatment. Incubation of platelets with clioquinol (100µM) resulted in increases of 
phosphorylation of both Erk1/2 and JNK (Fig 5). Quantification of immunoblots showed 
that clioquinol treatment resulted in increases in phosphorylation of Erk1/2 from 
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1.0±0.07 to 2.5±0.34AU, whilst JNK phosphorylation increased from 1.97±0.29AU to 
3.8±0.17AU relative to vehicle control (Figure 5a, p<0.05). A23187 treatment (100µM) 
did not significantly change the levels of phosphorylation of either Erk1/2 or JNK 
(Figure 5a). Further experiments were performed to investigate the role of Zn2+ in 
agonist-evoked phosphorylation events. Stimulation of platelets with thrombin (1U/mL) 
resulted increases in phosphorylation of Erk1/2 and JNK respectively. Phosphorylation 
of Erk1/2 increased from 2.0±0.2AU to 4.26±0.24AU, whilst JNK increased from 
1.6±0.52AU to 5.33±0.33AU, (Figure 5b, p<0.05). Agonist-evoked phosphorylation 
was abrogated in TPEN treated platelets (Erk1/2 phosphorylation was reduced to 
4.26±0.24, and JNK to 2.89±0.49 in TPEN pre-treatment platelets). Stimulation with 
CRP-XL (1μg/mL) did not result in phosphorylation of either kinase. These data 
indicate a specific signalling response leading to Erk1/2 and JNK phosphorylation that 
is dependent on Zn2+, and independent of Ca2+ 
Previous work has demonstrated an association between MAPK activity and 
Zn2+-mediated changes in the redox state in nucleated cells.[26,49] To investigate the 
role of the platelet redox state in Zn2+-mediated ROS production, DHE-loaded platelets 
were pre-treated with DPI (10µM) or mitoTEMPO (10µM) prior to stimulation with 
clioquinol (100µM). DPI or mitoTEMPO pre-treatment reduced Erk1/2 and JNK 
phosphorylation from 7.3±0.8 to 3.8±0.2 and 3.7±0.7AU respectively (Figure 6a-c). As 
A23187 treatment did not result in the phosphorylation of Erk1/2 or JNK, DPI or 
mitoTEMPO treatment had no additional effect. These analyses show that increasing 
cytosolic Zn2+, but not Ca2+ results in phosphorylation of both Erk1/2 and JNK, in a 
manner that is dependent on NADPH oxidase and mitochondria activity. 
Further experiments were performed to confirm the roles of Erk1/2 and JNK 
using the Erk1/2 and JNK inhibitors, U0126 (10µM) and SP600 (10µM) respectively. 
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Pretreatment with either of these inhibitors decreased A23187 or clioquinol-mediated 
DHE fluorescence (Figure 6d). A23187-mediated DHE fluorescence was reduced 
from 2310±317AU to 1399±134AU and 393±149AU respectively following U0128 and 
SP600 treatment (Figure 6d, p<0.05). Clioquinol mediated DHE fluorescence was 
reduced from 2390.0±318AU to 1022±128AU and 739±104AU respectively following 
U0128 and SP600 treatment (Figure 6d, p<0.05). These data indicate that Erk1/2 and 
JNK phosphorylation occur downstream of ionophore treatment. Given that A23187 
stimulation does not result in increases in Erk1/2 phosphorylation, these data indicate 
that Erk1/2 and JNK activation occurs as a result of changes in the concentration of 
cytosolic cations, and act on concert to regulate ROS production.  
 
Discussion 
The importance of ROS during platelet activation process is well documented. 
Stimulation of platelets with the conventional agonists, thrombin or CRP, results in 
increases in ROS production whilst the inhibitory effect of antioxidants function is 
correlated with a reduction in  platelet responses.[50] Additionally, platelets can be 
activated by both extra- and intracellular free radical species.[15,51] 
The influence of Zn2+ on ROS production in nucleated cells has been 
addressedFor example, in vitro studies showed that increases in cytosolic Zn2+ results 
in ROS generation in a number of nucleated cell systems.[27,31,52,53] 
Hitherto, the influence of Zn2+ on ROS generation in platelets has not been 
investigated. Platelets are potentially exposed to Zn2+ via different routes. Exogenous 
Zn2+ is available to platelets from rupture of atherosclerotic plaques, and via release 
from α granules of activated platelets. Previously, we have shown that exogenous Zn2+ 
is able to enter the platelet cytosol where it influences platelet activation.[11] 
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Chelation of [Zn2+]i reduced platelet aggregation in response to a variety of 
agonists, and also abrogated thrombus formation in an in vitro blood flow 
model.[11] Recently, we demonstrated that platelet stimulated with conventional 
platelet agonists induced dose-dependent increases of [Zn2+]I, indicating release of 
Zn2+ into the cytosol from intracellular stores, and consistent a role for Zn2+ as a 
secondary messenger.[12] 
Increases in [Zn2+]i are likely to modulate the activity of signalling pathways via 
the activation of kinases including PKC, CamKII and IRAK, in a similar way to Ca2+-
dependent signalling.[10,54,55] Whilst the influence of [Ca2+]i, on different redox 
systems and pathways is well documented, influences of [Zn2+]i on ROS generation is 
relatively unstudied.[56] 
In the present study we model increases in [Zn2+]i from endogenous and 
exogenous sources, and investigate the subsequent influence of, and mechanism of 
ROS generation. We demonstrate that increasing [Zn2+]i results in an increase in ROS 
generation, in a manner which is mediated by NADPH oxidase and mitochondria 
stimulation, and is regulated by Erk1/2 and JNK. Furthermore, we demonstrate that 
ROS production in response to platelet stimulation by conventional agonists (thrombin 
or CRP-XL) is also dependent on [Zn2+]i. Agonist stimulation results in increases in 
ROS production in a manner that is sensitive to intracellular Zn2+ chelation using 
TPEN. Whether agonist-dependent ROS stimulation is attributable to agonist-evoked 
increases in [Zn2+]i [57] or whether this represents a disruption of obligate Zn2+-binding 
proteins by TPEN, is not known. Using ZnSO4 as source of exogenous Zn2+, we found 
that Zn2+ dependent platelet stimulation results in increases in platelet ROS. 
Interestingly, whilst all Zn2+ concentrations tested result in increases in ROS, 
the lowest concentration of Zn2+ used (10µM) results in the greatest ROS 
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increases. As 10µM Zn2+ is sub-activatory, we speculate that activation 
responses may reduce ROS by activating antioxidant responses within 
platelets. This is an interesting observation that will be studied further. 
Ionophores were used to model increases of cation concentration on ROS 
generation. Importantly, whilst A23187 has been widely used to model increases in 
[Ca2+]i, it should be noted that this is a non-specific ionophore, with affinities for a wide 
variety of cations, including Zn2+. Conversely, clioquinol is specific for Zn2+ and its use 
does not affect [Ca2+]i.[12,42] Our data show that increases in the cytosolic 
concentration of either [Ca2+]i or [Zn2+]i correlates with increases in ROS. Whilst 
A23187-induced ROS generation could be attributable to Ca2+ or Zn2+ increases, ROS 
generation by clioquinol supports a role for [Zn2+]i in ROS generation that is 
independent of Ca2+. This is consistent with other work in nucleated cells, for example 
in cortical neurones, where ROS increases in response to treatment with the Zn2+ 
ionophore pyrithione.[31]  
Both agonist- and ionophore-evoked ROS production is accompanied by 
decreases in GSH and GPx activity. Acting as an antioxidant, GSH suppress the 
excess production of intracellular oxidants. The reaction between glutathione 
peroxidase (GPx) and hydrogen peroxide, or of GSH with peroxynitrite and other 
oxidants results in the generation of glutathione oxidized form, GSSG, which is a 
marker of oxidative stress.[58,59] By manipulation of [Zn2+]i levels using Zn2+ chelators 
and ionophores, we show that the levels of GSH and GPx activity are altered in a 
[Zn2+]i-dependent manner, confirming the involvement of [Zn2+]i and [Ca2+]i on platelet 
redox state modulation. These data are consistent with that of Bishop et al [52] who 




We performed experiments to investigate the mechanisms by which Zn2+ 
regulates ROS production in platelets. NADPH oxidases (of which NOX1 and NOX2 
isoforms are present in human platelets) are important ROS-generating enzymes. In 
neuronal cells, treatment with high concentrations of Zn2+ results in neurotoxicity that 
is associated with NADPH oxidase activation and PKC stimulation.[24] Alongside 
mitochondria activity, these enzymes regulate platelet activity via the regulation of 
redox- dependent ATP generation and ROS release.[60,61] 
  We examined the involvement of NOX and mitochondrial activity on [Zn2+]i-
dependent ROS using the NADPH oxidase inhibitor, DPI, and the mitochondrial 
targeted anti-oxidant, mitoTEMPO. Clioquinol-mediated ROS production was 
abrogated following pre-incubation of platelets with the DPI or mitoTEMPO, indicating 
a role for NADPH oxidase and mitochondria activity on [Zn2+]i–dependent ROS 
production. Our observations are supported by previous studies, which showed that 
increases in [Zn2+]i promote p47phox activity in a neurotoxic environment.[24,31,45]  
MAPK activity is critical for a number of intracellular signalling pathways in 
platelets, including αIIbβ3 activation, platelet granule release, thromboxane A2 (TxA2) 
generation, and cytoskeletal rearrangements leading to platelet spreading.[62,63] As 
Zn2+ has previously been shown to regulate MAPK activation in nucleated cells 
[47,64,65] we investigated the influence of increases in Zn2+ on MAPK activity in 
platelets. Ionophore-dependent increases in [Zn2+]i, but not [Ca2+]i resulted in 
increased phosphorylation of Erk1/2 and JNK, in a manner that has previously been 
observed in mouse thymocytes and splenic T cells. However, in contrast to our data 
phosphorylation of p38 MAPK was Ca2+ dependent, and JNK-1 activation was 
suppresses in a dose-dependent manner following incubation with A23187.[66] Such 
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scheme has also been seen in NIH-3T3 mouse fibroblasts, where A23187 treatment 
was also shown to  inhibits p38 MAPK phosphorylation].[67] 
Agonist-dependent MAPK stimulation is abrogated following chelation of [Zn2+]i. 
MAPK activation is modulated by cellular ROS levels, for example, in liver carcinoma 
cells (HepG2 cells), where ROS-JNK signalling promotes HBV-autophagosome 
formation.[68] LPS-mediated Nitric oxide (NO) release in response to Zn2+ treatment 
of astrocytes is associated with MAPK and NFκB activation.[49] Similar effects have 
been shown in renal cells, where Zn2+ promotes MAPK activation via ROS generation 
MAPK.[25, 26] Furthermore, in limb ischemia reperfusion, MAPKs are activated by 
ROS resulting in damage to distant organs.[69] Our results show that phosphorylation 
of Erk1/2 and JNK in platelets is regulated by [Zn2+]i-mediated ROS generation via 
NADPH oxidase and mitochondria. This is consistent with previous studies, for 
example, in alveolar macrophages, where it was shown that Erk/2 effects 
mitochondrial integrity and ATP production, and pre-treatment with MEK inhibitors 
decreases Nox-5 phosphorylation in COS-7 cells.[70] Furthermore, In response to 
LPS, JNK promotes the stimulation of NADPH oxidase during NETosis in 
neutrophils.[71] In this context, our data show that the induction of platelet ROS 
generation in response to increases in [Zn2]i, is reduced in response to Erk1/2 and 
JNK inhibitors, presenting a positive feedback loop between Zn2+-dependent ROS 
induction and MAPK phosphorylation. Given the importance of MAPKs in platelet 
activation leading to thrombus formation,[72] identification of Zn2+-sensitive MAPK 
activation in platelets may highlight a potentially significant route through leading to 
thrombus formation following plaque rupture.  
In summary, our findings establish an association between [Zn2+]i and ROS 
production in platelets, providing evidence that [Zn2+]i stimulates NADPH oxidase and 
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mitochondria via Erk1/2 and JNK activation, and these MAPKs promote an increase 
of ROS by a positive feedback (Figure 7). These data explain the involvement in Zn2+ 
in platelet redox balance, which is a key process during platelet activation.[15] 
Pharmacological manipulation of Zn2+ might be a potential strategy to moderate 
oxidative stress, which is a pivotal feature of cardiovascular diseases.  
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Figure 1. Exogenous Zn2+ stimulates ROS production by platelets. Platelet 
suspensions were loaded with the ROS-sensitive dye, DHE (10µM) and stimulated 
with increasing concentrations of Zn2+. Changes in the fluorescent signal after 10 min 
were quantified by flow cytometry (a). Results are presented as means ± SEM of 7 
independent experiments. Significance is denoted as *** (P<0.001), ** (P<0.01), or * 
(P<0.05). ESR was used to further demonstrate Zn2+-dependent superoxide anion 
production. Platelet suspensions were loaded with superoxide-specific spin probe 
CMH and treated for Platelets were treated for 45 minutes with 200μM dRP, vehicle 
(Tyrode’s buffer, black) or 10µM (blue), 30µM (grey), 100µM (red) or 300µM (green) 
of ZnSO4 in the presence of CMH (200μM) prior to ESR analysis. The trace is 
representative of 3 independent experiments (b).   
 
Figure 2. ROS production in response to platelet stimulation is dependent on 
[Zn2+]i. DHE-loaded washed platelet suspensions were pre-incubated with the 
intracellular Zn2+ chelator, TPEN (50μM) prior to stimulation with thrombin (1U/mL) or 
CRP-XL (1μg/mL). Changes in DHE fluorescence were analysed by flow cytometry 
(a). Changes to glutathione (GSH) (b) and glutathione peroxidase activity (GPx) (c) in 
response to Zn2+ were measured by ELISA. Results are presented as means ± SEM 
values of between 3 and 5 experiments. Significance is denoted as *** (P<0.001), ** 
(P<0.01), or * (P<0.05). 
 
Figure 3. Increasing platelet [Zn2+]i by stimulation with Zn2+ ionophores results 




stimulated with clioquinol (100µM) or A23187 (100µM), and fluorescence changes 
were quantified using flow cytometry (a). Superoxide anion production following 
ionophore stimulation was observed using ESR (b). Green: A23197 (100µM), red: 
clioquinol (100µM), black: vehicle control. To visualise ionophore-dependent ROS 
production, platelets were loaded with DHE and imaged using confocal microscopy 
following stimulation with clioquinol (100µM) or A23187 (100µM) (c). In order to 
quantify ROS-dependent changes in response to increasing concentrations of [Zn2+]i, 
washed platelet suspensions were incubated with clioquinol (100µM) or A23187 
(100µM) for 10min. Reduced glutathione (GSH) (d) and glutathione peroxidase activity 
(GPx) (e) were quantified by ELISA. Results are presented as mean ± SEM values of 
between 3 and 5 experiments. Significance is denoted as * (P<0.05). 
 
Figure 4. [Zn2+]i-mediated ROS generation is regulated by NADPH oxidase and 
mitochondria activation. DHE-loaded washed platelet suspensions were pre-
incubated with the NADPH oxidase inhibitor diphenyleneiodonium (DPI, 10µM) or the 
mitochondrial targeted anti-oxidant mitoTEMPO (Mito, 10µM). After stimulation with 
clioquinol (100µM) or A23187 (100µM), ROS generation was analysed by flow 
cytometry. Results are representative of 6 independent experiments (a). Washed 
platelet suspensions were stimulated with clioquinol (100µM) or A23187 (100µM), 
after which they were subjected to subcellular fractionation, and phosphorylation of 
p47phox was analysed by immunoblotting (b). The immunoblot is representative of 3 
independent experiments. Blots were analysed using densitometry (c). Results are 





Figure 5. Agonist-dependent MAPK activation is dependent on [Zn2+]i. Washed 
platelet suspensions were stimulated with clioquinol (100µM) or A23187 (100µM) (a), 
or pre-incubated with TPEN (50μM) followed stimulation by thrombin (1U/mL) or CRP-
XL (1μg/mL) (d). After subcellular fractionation, phosphorylation of Erk1/2 or JNK was 
analysed by Immunoblotting. Graphs show densitometric analysis of immunoreactive 
bands P-Erk (a, b, d, e), or P-JNK (a, c, d, f). Results are presented as means ± SEM 
values of 3 independent experiments. Significance is denoted as *** (P<0.001), ** 
(P<0.01), or * (P<0.05).  
 
Figure 6. Zn2+, but not Ca2+-mediated ROS generation induces Erk1/2 and JNK 
phosphorylation. Washed platelet suspensions were pre-incubated with DPI (10µM) 
or mitoTEMPO (Mito, 10µM) prior to stimulation with clioquinol (100µM) or A23187 
(100µM). Phosphorylation of Erk1/2, or JNK were examined by immunoblotting as 
before (a-c). Blots are representative of 3 separate experiments. DHE-loaded washed 
platelet suspensions were pretreated with the Erk1/2 and JNK inhibitors U0126 (10µM) 
and SP600 (10µM) respectively, prior to stimulation with A23187 (100µM) or clioquinol 
(100µM). Changes in DHE fluorescence were quantified using flow cytometry (d). 
Results are presented as means ± SEM. Significance is denoted as *** (P<0.001), ** 
(P<0.01) or * (P<0.05). 
 
Figure 7: Schematic showing the proposed role of Zn2+ in platelet ROS 
generation. Agonist stimulation (1) or local increases in plasma Zn2+ as a result of 
platelet degranulation or atherosclerotic plaque rupture (2) result in increases in [Zn2+]i 
(3). Increases in [Zn2+]i results in the activation of NADPH oxidase (4) and 
mitochondria (5), resulting in an increase of ROS generation (6). ROS-mediated 
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phosphorylation of the MAPKs, Erk1/2 and JNK results in a positive feedback loop in 
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